Skip to main content
Fig. 4 | Diabetology & Metabolic Syndrome

Fig. 4

From: Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Fig. 4

Summary of count data analysis with random effects or fixed effects ORs (95% CI) estimate with a p-value for analysis of primary safety outcomes. *Statistically significant variables at P value < 0.05. a All adverse events, b gastrointestinal events, c decreased appetite, d hypoglycemic events, e discontinuation of therapy, f serious adverse events, g fatal adverse event

Back to article page